59 results about "Gene panel" patented technology

A method for the development of gene panels for diagnostic and therapeutic purposes comprising the steps of: (a) isolating at least one biological sample from each of at least two groups of biological material containing mRNA and/or proteins; (b) analyzing the expression level of at least one gene in the at least one biological sample; (c) selecting the gene(s) exhibiting a different expression level between the at least two groups of biological material, whereby a first knowledge base is generated; (d) analyzing the level of cytosine methylation in the methylation relevant regions of at least one gene of at least one of the biological samples of step (a), wherein the gene is selected on the basis of the first knowledge base; (e) selecting the gene(s) exhibiting a different level of cytosine methylation between the at least two groups of biological material, whereby a second knowledge base is generated; and (f) adding selected genes from the second knowledge base to a gene panel.

A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.

The invention relates to the fields of biotechnology, DNA mutation detection technology and bioinformatics, in particular to a gene panel for predicting a new antigen load and detecting genome mutation. Specifically, the invention relates to the gene panel which combines 839 genes and integrates 511 gene fusion events. The gene panel provided by the invention can rapidly, efficiently and accurately predict a new antigen load, and can also detect DNA mutation of multiple sites at one time, so that an optimal individualized treatment drug and scheme can be selected according to genomic characteristics of a patient in a cancer immunotherapy process. In addition, the gene panel provided by the invention can also be used for measuring various types of biomarkers such as SNV, Indel, CNV, gene fusion, MSI, TMB and HLA.

The present invention relates to the use of molecular risk marker profiles for diagnosis of Parkinson's disease. More particularly, the invention provides methods for diagnosis of Parkinson's disease in an individual, utilizing certain profiles established based on the expression levels of certain genes, which together form a gene panel, in the peripheral blood of said individual, as well as kits for carrying out these methods. The profile encompass ALDH1A1.

The present invention relates to markers for high-grade serous ovarian cancer (HG-SOC) and methods and uses thereof for diagnosing high-grade serous ovarian cancer (HG-SOC) and/or determining the prognosis of a subject suffering from high-grade serous ovarian cancer (HG-SOC) by determining the presence or absence of a mutation in a CHEK2 marker or mutations of markers from a 21 -gene panel comprising ADAMTSL3, ATR, CHEK2, ENAH, ERN2, GLI2, GYPB, KIAA1324L, LRRN2, MAP3K6, MAPK15, MET, MLL4, NIPBL, PCDH15, PPP1CC, PTCH1, PTK2B, RPS6KA2, RSU1 and TNC. It also relates to the use of markers CHEK2, RPS6KA2 and MLL4 in predicting the risk of developing high-grade ovarian serous ovarian cancer by determining germline mutations in at least one of these three markers.

Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.

Provided herein are methods, compositions, systems, and kits for diagnosing acute rejection of solid organ transplants using at least 5 genes selected from a 10-gene panel.

The present invention provides for methods, reagents, apparatuses, and systems for the replication or amplification of nucleic acid molecules from biological samples. In one embodiment of the invention, the nucleic molecules are isolated from the sample, and subjected to fragmenting and joining using ligating agents of one or more hairpin structures to each end of the fragmented nucleic molecules to form one or more dumbbell templates. The one or more dumbbell templates are contacted with at least one substantially complementary primer attached to a substrate, and subjected to rolling circle replication or rolling circle amplification. The resulting replicated dumbbell templates or amplified dumbbell templates are used in numerous genomic applications, including whole genome de novo sequencing; sequence variant detection, structural variant detection, determining the phase of molecular haplotypes, molecular counting for aneuploidy detection; targeted sequencing of gene panels, whole exome, or chromosomal regions for sequence variant detection, structural variant detection, determining the phase of molecular haplotypes and/or molecular counting for aneuploidy detection; study of nucleic acid-nucleic acid binding interactions, nucleic acid-protein binding interactions, and nucleic acid molecule expression arrays; and testing of the effects of small molecule inhibitors or activators or nucleic acid therapeutics.

The invention relates to the technical field of biomedicine and particularly provides a liquid phase gene panel capture kit for detecting genes related to pulmonary thromboembolism and application thereof. The liquid phase gene panel capture kit comprises a capture probe covering 92 genes. The design of the gene panel capture kit integrates multi-level and multi-aspect genetic factors of pulmonaryembolism, is comprehensive in coverage and has obvious pertinence in target capture, genetic detection can be simultaneously conducted on genes with large fluxes, sequencing depth and coverage degreeof the genes can be effectively improved by efficiently enriching DNA of exon areas of target genes of people and adopting subsequent sequencing, and guarantee is provided for obtaining of more accurate gene genetic information and results.

The invention discloses a gene panel for detecting single-gene genetic hypertension and application of a gene panel. By means of the gene panel, potential pathogenic gene mutation of single-gene genetic hypertension can be screened out of massive genetic information by means of targeted high-throughput sequencing in combination of a bioinformatics analysis means, and the positive detection rate ofmutation sites of single-gene genetic hypertension and application can be remarkably increased. The detection result of the gene panel is combined with clinical phenotype of a patient, etiological diagnosis of single-gene genetic hypertension and application of gene panel can be effectively assisted, and therefore the clinical disease diagnosis rate is increased, a specific and effective intervention treatment scheme is implemented aiming to specific illness states, and the effects of early finding, early intervention and prognosis improvement on single-gene genetic hypertension are achieved.According to the technical scheme, the remarkable advantages of being high in gene detection speed, high in disease diagnosis accurate and the like are achieved.

The invention discloses a cancer gene detection kit based on a second-generation sequencing probe capture method. The cancer gene detection kit comprises quality control materials, library building reagents and an RNA probe; quality control materials: a negative quality control material and a positive quality control material; library building reagents: a tail end repairing and A adding reagent, ajoint adding reagent, an amplification reagent, a hybridization reagent, a capture reagent and an amplification reagent; the RNA probe is a probe panel; the synthesis type of the RNA probe is an RNAsingle strand; the length interval is 90-120 nt; and biotin is marked. The cancer gene detection kit in the invention aims at patients with lung cancer, colorectal cancer, breast cancer and ovarian cancer. Detection of 18 genes panel is carried out; the receptivity of medicines, such as targeting and chemotherapy, on a patient is comprehensively interpreted from the gene level; according to the difference of individual gene levels, an accurate personalized treatment scheme is made; immune medication treatment is guided; the sensitivity and toxic and side effects of chemotherapy drugs are predicted; a medication prognosis condition is dynamically monitored, etc.

Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and/or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and/or RCC patient is also presented.

The invention relates to the field of biomedical technologies and disease diagnosis, and particularly discloses a gene panel capture kit for detecting genetic mutation of a pathogenic gene of Immotilecilia syndrome and application of the gene panel capture kit. The liquid phase capture kit of the gene panel comprises 49 probes corresponding to the related pathogenic gene of the Immotile cilia syndrome. The design of the gene panel capture kitsynthesizes the pathogenic factors of the Immotile cilia syndrome genetic defects of cilia immobility syndrome in multiple layers and aspects, comprehensive covering is achieved, the target capture of the gene panel capture kit has obvious pertinence, and the pathogenic gene with large flux can be accurately and simultaneously captured and genetic-detected. Human target gene exon region DNA is efficiently enriched, and then high-throughput and high-depth sequencing is conducted on a second generation sequencing platform, the depth and coverage ofgene sequencing can be effectively improved, and convenience is provided for obtaining more accurate genetic mutation information of gene pathogenicity and disease prevention and diagnosis.

The invention belongs to the technical field of nervous system tumor multi-gene detection, and discloses a gene panel for detecting nervous system tumors, important exon regions and partial intron regions of 454 genes are enriched by using a biological probe hybridization method, and the detection and analysis contents comprise somatic mutation, embryonic mutation, copy number variation, fusion gene and other variation, which aims to achieve accurate detection. The multi-gene screening list is made into a probe, high-risk genes are detected in a targeted mode through hybridization capture sequencing, gene mutation with guiding significance on diagnosis and treatment can be detected more efficiently, the gene detection cost of patients and the operation difficulty of experimenters can be reduced, meanwhile, some tumor patients can be possibly helped to participate in clinical tests, and important guiding significance is provided for clinical diagnosis and discovery of target spots of targeted therapy.

The invention discloses a method for constructing a tumor mutation load TMB panel. The method comprises the following steps: 1) acquiring transcriptome data of a tumor patient, and dividing the transcriptome data into a high TMB group and a low TMB group; 2) screening immune-related differential expression genes DEGs between the high TMB group and the low TMB group, and carrying out enrichment analysis; 3) carrying out immune cell infiltration analysis through Immune CellAI, and screening out potential key immune cells; 4) screening out tumor immunity related genes for prognosis of the patient; 5) establishing modules with different colors and a correlation matrix of immune traits possibly influencing prognosis; and 6) selecting genes with better correlation with macrophages, DC, MAIT andinfiltration integration in the WCGNA, and preliminarily obtaining a TMBIF gene panel. The invention also provides a using method of the tumor mutation load TMB panel. The tumor mutation load TMB panel constructed by the invention is low in sequencing cost and low in DNA input requirement in use, has shorter turnover time, can perform deeper sequencing, and improves the mutation detection sensitivity.

The invention relates to the field of gene detection technology, in particular to a kit for detecting idiopathic azoospermia and a gene panel. A small amount of (3 ml) peripheral blood from a patientis utilized to extract DNA, gene mutation of the patient is detected through library-establishing, high-throughput sequencing, etc., and through bioinformatics analysis, such as mutation frequency, mutation property, biological harm and conservative property, evaluation is performed to find 30 new morbigenous genetic mutations in the patient. Only 3 ml of peripheral blood of the patient is neededfor detection and 30 detection sites are covered, thereby improving the detection rate of the mutation, and 30 sites are carried out in one reaction system, to greatly reduce the workload, improve work efficiency, and save work time.

The invention discloses a gene Panel for detecting a generic cancer species, a probe and application of the gene Panel. The gene Panel comprises a tumor pathway related gene, a tumor genetic susceptibility gene, a tumor high-frequency mutant gene, a tumor targeted drug related gene, a tumor driving gene, an immune therapeutic effect related gene, a key DDR pathway related gene and other genes playing an important role in cancer generation and development. The gene Panel can be used for detecting all biomarkers corresponding to solid tumor targeted drugs approved by the State Drug Administration (NMPA)/American Food and Drug Administration (FDA) to appear in the market at a time, so that accurate treatment of tumors is fully guided. Prognosis of a subject can be evaluated, the recurrence risk of the subject is layered, and postoperative adjuvant therapy is guided; besides, hereditary tumor evaluation can be carried out on a subject, family genetic risks are prompted, and early discovery, early diagnosis and early treatment are achieved.

A gene panel comprising a group of genes of which expression levels change in hepatocytes during liver regeneration as compared with those in a normal state is produced by the following steps: (a) the step of measuring expression levels of various genes in hepatocytes of a model animal in a normal state and expression levels of the genes during liver regeneration; (b) the step of comparing the expression levels, respectively; and (c) the step of identifying a group of genes of which expression levels change during liver regeneration.